Stock comparison
Mettler-Toledo International
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.21B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 65B | MTD |
| Benjamin Graham | 65B | 61C | MTD |
| Philip Fisher | 63C | 73B | NVO |
| Peter Lynch | 66B | 57C | MTD |
| Joel Greenblatt | 68B | 56C | MTD |
| Charlie Munger | 74B | 76B | NVO |
| Terry Smith | 70B | 72C | NVO |
Side-by-side metrics
| Metric | MTD | NVO |
|---|---|---|
| Market cap | $22.29B | $199.21B |
| P/E (TTM) | 25.3x | 10.4x |
| EV/EBIT | 21.6x | 10.9x |
| ROIC (TTM) | 36.09% | 32.2% |
| Gross margin | 57.79% | 81.85% |
| Net margin | 21.4% | 37.2% |
| Revenue CAGR 5y | 2.01% | 21.72% |
| EPS CAGR 5y | 6.12% | 22.03% |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 0.7x+101%
- ROIC (TTM)36.09%vs 32.2%+11%
NVO leads on
- Dividend yield4.09%vs 0.0%+100%
- Revenue CAGR 5y21.72%vs 2.01%+91%
- Market cap$199.21Bvs $22.29B+89%
- EPS CAGR 5y22.03%vs 6.12%+72%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.